308 related articles for article (PubMed ID: 18216297)
1. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes.
Wernig G; Gonneville JR; Crowley BJ; Rodrigues MS; Reddy MM; Hudon HE; Walz C; Reiter A; Podar K; Royer Y; Constantinescu SN; Tomasson MH; Griffin JD; Gilliland DG; Sattler M
Blood; 2008 Apr; 111(7):3751-9. PubMed ID: 18216297
[TBL] [Abstract][Full Text] [Related]
2. STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant.
Funakoshi-Tago M; Tago K; Abe M; Sonoda Y; Kasahara T
J Biol Chem; 2010 Feb; 285(8):5296-307. PubMed ID: 20028972
[TBL] [Abstract][Full Text] [Related]
3. Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis.
Ueda F; Tago K; Tamura H; Funakoshi-Tago M
J Biol Chem; 2017 Feb; 292(5):1826-1846. PubMed ID: 27998978
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine 201 is required for constitutive activation of JAK2V617F and efficient induction of myeloproliferative disease in mice.
Yan D; Hutchison RE; Mohi G
Blood; 2012 Aug; 120(9):1888-98. PubMed ID: 22837531
[TBL] [Abstract][Full Text] [Related]
5. Induction of tyrosine phosphorylation of Vav and expression of Pim-1 correlates with Jak2-mediated growth signaling from the erythropoietin receptor.
Miura O; Miura Y; Nakamura N; Quelle FW; Witthuhn BA; Ihle JN; Aoki N
Blood; 1994 Dec; 84(12):4135-41. PubMed ID: 7527668
[TBL] [Abstract][Full Text] [Related]
6. The indispensable role of the RNA helicase DDX5 in tumorigenesis induced by the myeloproliferative neoplasm-associated JAK2V617F mutant.
Takeda K; Tago K; Funakoshi-Tago M
Cell Signal; 2023 Feb; 102():110537. PubMed ID: 36442590
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine-phosphorylated SOCS3 negatively regulates cellular transformation mediated by the myeloproliferative neoplasm-associated JAK2 V617F mutant.
Funakoshi-Tago M; Tsuruya R; Ueda F; Ishihara A; Kasahara T; Tamura H; Tago K
Cytokine; 2019 Nov; 123():154753. PubMed ID: 31255914
[TBL] [Abstract][Full Text] [Related]
8. Activated Jak2 with the V617F point mutation promotes G1/S phase transition.
Walz C; Crowley BJ; Hudon HE; Gramlich JL; Neuberg DS; Podar K; Griffin JD; Sattler M
J Biol Chem; 2006 Jun; 281(26):18177-83. PubMed ID: 16632470
[TBL] [Abstract][Full Text] [Related]
9. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.
Lu X; Levine R; Tong W; Wernig G; Pikman Y; Zarnegar S; Gilliland DG; Lodish H
Proc Natl Acad Sci U S A; 2005 Dec; 102(52):18962-7. PubMed ID: 16365288
[TBL] [Abstract][Full Text] [Related]
10. Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F.
Lu X; Huang LJ; Lodish HF
J Biol Chem; 2008 Feb; 283(9):5258-66. PubMed ID: 18158285
[TBL] [Abstract][Full Text] [Related]
11. Akt activation through the phosphorylation of erythropoietin receptor at tyrosine 479 is required for myeloproliferative disorder-associated JAK2 V617F mutant-induced cellular transformation.
Kamishimoto J; Tago K; Kasahara T; Funakoshi-Tago M
Cell Signal; 2011 May; 23(5):849-56. PubMed ID: 21255641
[TBL] [Abstract][Full Text] [Related]
12. A human erythropoietin receptor gene mutant causing familial erythrocytosis is associated with deregulation of the rates of Jak2 and Stat5 inactivation.
Arcasoy MO; Harris KW; Forget BG
Exp Hematol; 1999 Jan; 27(1):63-74. PubMed ID: 9923445
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylated CIS suppresses the Epo or JAK2 V617F mutant-triggered cell proliferation through binding to EpoR.
Funakoshi-Tago M; Moriwaki T; Ueda F; Tamura H; Kasahara T; Tago K
Cell Signal; 2017 Feb; 31():41-57. PubMed ID: 28038963
[TBL] [Abstract][Full Text] [Related]
14. Critical roles of Myc-ODC axis in the cellular transformation induced by myeloproliferative neoplasm-associated JAK2 V617F mutant.
Funakoshi-Tago M; Sumi K; Kasahara T; Tago K
PLoS One; 2013; 8(1):e52844. PubMed ID: 23300995
[TBL] [Abstract][Full Text] [Related]
15. Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways.
Tong W; Zhang J; Lodish HF
Blood; 2005 Jun; 105(12):4604-12. PubMed ID: 15705783
[TBL] [Abstract][Full Text] [Related]
16. [Analysis of the mechanism of polycythemia vera by studying JAK2 mutant-induced signaling pathway].
Funakoshi-Tago M
Yakugaku Zasshi; 2011; 131(8):1183-7. PubMed ID: 21804321
[TBL] [Abstract][Full Text] [Related]
17. Mitogen-activated protein kinase plays an essential role in the erythropoietin-dependent proliferation of CTLL-2 cells.
Sakamoto H; Kitamura T; Yoshimura A
J Biol Chem; 2000 Nov; 275(46):35857-62. PubMed ID: 10960479
[TBL] [Abstract][Full Text] [Related]
18. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
[TBL] [Abstract][Full Text] [Related]
19. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.
Adam M; Pogacic V; Bendit M; Chappuis R; Nawijn MC; Duyster J; Fox CJ; Thompson CB; Cools J; Schwaller J
Cancer Res; 2006 Apr; 66(7):3828-35. PubMed ID: 16585210
[TBL] [Abstract][Full Text] [Related]
20. SOCS2: inhibitor of JAK2V617F-mediated signal transduction.
Quentmeier H; Geffers R; Jost E; Macleod RA; Nagel S; Röhrs S; Romani J; Scherr M; Zaborski M; Drexler HG
Leukemia; 2008 Dec; 22(12):2169-75. PubMed ID: 18769447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
